VRDN Lumvoa IV launch draws prescriber engagement and robust demand
VRDN says its Lumvoa IV launch is seeing broad prescriber engagement and robust demand, supported by streamlined patient access and payer strategies. The company also points to pipeline progress including a sub-Q BLA submission in Q1 2027.